{"id":4537,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/interferon-alfa-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"interferon-alfa-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/interferon-alfa-txt\/","title":{"rendered":"interferon alfa.txt"},"content":{"rendered":"

interferon alfa <\/h1>\n

CLINICAL USE <\/H3>
\n1. Hairy cell leukaemia2. AIDS related Kaposi\u2019s sarcoma3. Chronic myelogenous leukaemia4. Cutaneous T-cell lymphoma5. Chronic hepatitis B6. Chronic hepatitis C7. Follicular non-Hodgkin\u2019s lymphoma8. Advanced renal cell carcinoma9. Malignant melanoma

DOSE IN NORMAL RENAL FUNCTION <\/H3>1. Hairy cell leukaemia: 1.5\u20133 million IU daily or 3 times per week2. AIDS related Kaposi\u2019s sarcoma: 3\u201336 million IU daily or 3 times per week3. Chronic myelogenous leukaemia: 3\u20139 million IU daily or 3 times per week4. Cutaneous T-cell lymphoma: 3\u201318 million IU daily or 3 times per week5. Chronic hepatitis B: 2.5\u20135 million IU\/m2 3 times per week6. Chronic hepatitis C: 3\u20136 million IU 3 times per week7. Follicular non-Hodgkin\u2019s lymphoma: 6 million IU\/m2 on days 22\u201326 of each 28 day cycle8. Advanced renal cell carcinoma: 9\u201318 million IU 3 times per week9. Malignant melanoma: 1.5\u20133 million IU 3 times a week

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :19 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Negligible<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3.7\u20138.5\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function Monitor renal function closely
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function Monitor renal function closely
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with great caution.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsImmunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effect

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>SC, IM

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Interferon up-regulates the cell surface presentation of class II histocompatibility antigens, which raises the possibility of drug-induced allograft rejection. There are numerous clinical reports of allograft rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should be exercised in the use of interferon after renal transplantationInterferon is metabolised primarily in the kidney. It is excreted in the urine, but is reabsorbed by the tubules where it undergoes lysosomal degradation. In patients undergoing haemodialysis, the interferon molecule may accumulate as it is too large to be dialysed and will not undergo renal degradation. Hence, the dose may need to be adjusted
    \n","protected":false},"excerpt":{"rendered":"

    interferon alfa CLINICAL USE 1. Hairy cell leukaemia2. AIDS related<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4537","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4537"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4537\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}